FINWIRES · TerminalLIVE
FINWIRES

IsoEnergy Announcing New At-The-Market Equity Program

-- IsoEnergy (ISO.TO) over the weekend said it entered into an equity distribution agreement with Virtu Canada Corp and Virtu Americas LLC.

The company said that, pursuant to the distribution agreement, it may distribute up to C$50 million (or its equivalent in other currencies) of common shares in the capital of the company, from time to time through the agents. The company further said that this ATM program replaces its previous at-the-market equity program announced on June 2, 2025, which has since been terminated.

The company added that the TSX has conditionally approved the listing of the common shares that may be issued under the ATM program, and the company has applied for authorization from the NYSE American for the listing of such common shares.

"The ATM Program will be effective until the earlier of the issuance and sale of all of the Common Shares issuable pursuant to the ATM Program and the date that the ATM Program is otherwise terminated pursuant to the terms of the Distribution Agreement," said the company.

The company plans to use the net proceeds from the ATM program, if any, for general corporate purposes, which may include funding of corporate and project overhead expenses, financing of capital expenditures, repayment of indebtedness, technical studies and exploration in the United States and Australia and additions to working capital.

"Maintaining an at-the-market equity program provides IsoEnergy with additional financial flexibility and an efficient supplemental capital markets tool that can be used selectively, if and when appropriate," said Philip Williams, Chief Executive Officer and Director of IsoEnergy. "With a strong cash position of $135.1 million and equity portfolio of $52.6 million, we are well funded to execute on our current plans, and the ATM Program is not being established to address any immediate capital requirements. Instead, it preserves optionality, allowing the Company to act opportunistically in support of future growth, strategic initiatives, and balance sheet strength."

相關文章

Asia

Dizal Pharma將在美國臨床腫瘤學會年會上發表三種藥物的研究成果。

根據週三在上海證券交易所發布的公告顯示,江蘇迪扎爾製藥(SHA:688192)表示,將在美國臨床腫瘤學會(ASCO)年會上公佈其新藥sunvozertinib片劑、golidocitinib膠囊和DZD6008的最新研究成果。 sunvozertinib和DZD6008皆用於治療非小細胞肺癌,而golidocitinib則用於治療T細胞淋巴瘤。研究結果顯示,這些藥物均取得了正面成果,尤其是DZD6008,其具有顯著的抗腫瘤活性且安全性良好。 該生技公司的股價在午盤交易中上漲不到2%。

$SHA:688192
Asia

Critica將於3月季度啟動西澳大利亞稀土計畫範圍界定研究。

根據週三提交給澳洲證券交易所的文件顯示,Critica(ASX:CRI)表示,位於西澳大利亞的Jupiter稀土計畫的初步研究已於今年3月季度正式啟動。 該研究整合了選礦、下游加工、基礎設施和開發假設,旨在確定一個基準開發路徑。 公司計劃在6月季度繼續完成Jupiter專案140個鑽孔的資源升級鑽探工作。此外,該公司還計劃準備並運送20,000公斤散裝樣品進行中試規模處理,以支援持續的最佳化、性能提升和中間精礦的生產。

$ASX:CRI
Asia

北太平洋銀行的收購要約確保了對卡里爾銀行的控制權

北太平洋銀行(東京證券交易所代號:8524)週三在東京證券交易所發佈公告稱,其對Career Bank的股份收購要約已獲成功,持股比例增至88.26%,使Career Bank成為其子公司。 北太平洋銀行此次收購了852,487股Career Bank股份,超過了完成交易所需的最低收購數量。 交易結算將於4月28日開始,屆時Career Bank將正式併入北太平洋銀行的財務報表。 北太平洋銀行計劃啟動相關程序,使Career Bank成為其全資子公司,並將其股票從札幌證券交易所下市。此次收購總成本約為15億日圓。

$TYO:8524